Royalty Report: Drugs, Cancer, Disease – Collection: 299281


Curated Royalty Rate Report
Created On: 2020-07-15, Record Count: 11


This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Created On: 2020-07-15
Record Count: 11

Primary Industries

  • Drugs
  • Cancer
  • Disease
  • Pharmaceuticals
  • Proteins
  • Therapeutic
  • Biotechnology
  • Antibody
  • DNA
  • Drug Discovery

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 299281

License Grant
University grants a worldwide, exclusive license under the Patent Rights to make and have made, to use and have used, and to offer to sell, sell or import, and have offered to sell, sold or imported, the Licensed Products in the Field of Use, and to practice and have practiced the Licensed Processes and Know-How.

University also grants the right to enter into sublicensing agreements under the Patent Rights.

License Property
The University rights are for the Method for Synthesizing Epothilones and Epothilone Analogs and any other U.S. application owned by the University that has Valid Claims covering the manufacture, use, or sale of [trans-9,10-dehydro-epothilon,D].

Epothilones inhibit cell division with a mechanism of action similar to taxanes, one of the most successful classes of anti-tumor agents.

KOS-1584 is our epothilone anticancer clinical candidate that is being evaluated in dose-escalating Phase 1 clinical trials in patients with solid tumors.

Field of Use
The Licensee is developing its epothilone, KOS-1584, in Phase 1 clinical trials and it has shown activity in patients with non-small cell lung, ovarian, breast, pancreatic, prostate and other cancers.

IPSCIO Record ID: 282837

License Grant
For Exclusive Screening Anticancer Activity,  during the term of this agreement, Licensee shall have the exclusive right to screen Collaboration Compounds for Anticancer Activity.  Until the termination of this agreement,  Licensor agrees that  it shall not grant a Third Party the right to screen or develop the Collaboration Compounds, and except in connection with the Research Program, shall not itself screen or develop the Collaboration Compounds for Anticancer Activity.

For the Research License,  Licensor grants an exclusive, with no right to grant sublicenses, under Licensor Patent Rights and Licensor Know-How to make and use methods and materials to carry out the Research Program during the Research Term.

For the Screening License, Licensor grants an exclusive, worldwide license during the term of this agreement to use the Collaboration compounds to conduct screening for anticancer activity.

For the Development and Commercialization License, Licensor grants a worldwide, exclusive license, with the right to grant sublicenses, under the Licensor Patent Rights and Licensor Know-How, to make, use, and develop Collaboration Compounds, and, to make, have made, use, import, offer for sale, sell, and have sold products in the field.

This agreement includes a non-exclusive grant back from Licensee to Licensor.

License Property
The technology is the discovery and development of Epothilones.

Epothilone shall mean epothilone A, epothilone B, epothilone C, epothilone D, epothilone E, epothilone F, desoxyepothilone F, and any intermediate, derivative, or analog of any of the foregoing compounds.

Product shall mean any pharmaceutical product containing a Collaboration Compound that is selected for development and/or marketing by Licensee or its Affiliates or Sublicensees.

Collaboration Compounds shall mean any Epothilone claimed in Licensor patent rights.

Field of Use
The epothilones are a class of potential cancer drugs. Like taxanes, they prevent cancer cells from dividing by interfering with tubulin, but in early trials epothilones have better efficacy and milder adverse effects than taxanes.

The field shall mean the research, development, manufacture, use, and sale of any Collaboration Compound for any purpose, including but not limited to all human and animal pharmaceutical and agricultural applications.

IPSCIO Record ID: 238988

License Grant
Licensor grants a sole and exclusive license to the Swiss Licensee, with a right to sublicense, under the Licensor Patent Rights and Licensor Know-How to develop, use, sell, offer for sale, import and/or export Compounds and Licensed Products in the Territory and in the Field, and make and have made Compounds and Licensed Products in the Territory for such development, use, sale, offering for sale, importation and/or exportation.
License Property
Licensor owns or possesses certain patent rights, know-how and regulatory filings with respect to epothilones, including epothilone D, and believes that epothilone D has the potential to become an anti-cancer agent.

Compound means any epothilone, or analog, derivative, prodrug or metabolite of an epothilone, including but not limited to epothilone A, B, C and D, a compound that is analog, derivative, prodrug or metabolite of an epothilone, including but not limited to epothilone A, B, C and D, and any compound identified in scientific journals or patent publications as an epothilon, analog, derivative, prodrug or metabolite.

Back-Up Compound means a Compound other than epothilone D that may be suitable for development for use in the Field, until and unless it comes to be included in a Replacement Licensed Product.

Licensed Product means any product containing a Compound, the Commercialization of which would either use Licensor Know-How, including without limitation because the product was researched or developed using Licensor Know-How or but for this Agreement, infringe a Valid Claim.

Field of Use
Field means the treatment, palliation, and/or prevention of cancer.  Potential applications include breast cancer and non-hodgkin lymphoma.

IPSCIO Record ID: 29382

License Grant
Ixabepilone was developed by the Company, but is subject to a License Agreement with a German Licensor, relating to epothilone technologies.
License Property
Ixabepilone (INN; also known as azaepothilone B, codenamed BMS-247550) is an epothilone B analog[1] developed as a cancer drug.  Ixempra(ixabepilone) is a microtubule inhibitor belonging to a class of antineoplastic agents, the epothilones and their analogs.

The Company manufactures its bulk requirements for ixabepilone in its own facilities including the manufacturing of the active ingredient. The drug product which comprises a pharmaceutical kit is finished by Baxter Oncology GmbH.

Field of Use
In October 2007, the FDA approved ixabepilone in combination with capecitabine for the treatment of patients with metastatic or locally advanced breast cancer resistant to treatment with an anthracycline and a taxane, or whose cancer is taxane resistant and for whom further anthracycline therapy is contraindicated, and in monotherapy for the treatment of metastatic or locally advanced breast cancer in patients whose tumors are resistant or refractory to anthracyclines, taxanes, and capecitabine.

IPSCIO Record ID: 256273

License Grant
The German Licensor grants the Swiss Licensee a worldwide, exclusive, right and license, or sublicense, with the right to grant sublicenses, under the Licensed Technology to make, have made, use, offer for sale, sell, and import the Product in the Field in the Territory.

This agreement includes a non-exclusive grant by Licensee to Licensor.

License Property
Licensor is developing a pharmaceutical product comprising a human antibody of IgG-1 subtype binding to EpCAM.

The patents include Novel Method for the Production of anti-human Antigen Receptors and Uses thereof, and, Anti-EpCAM Immunoglobulins.

Decatumumab (MT201) is a recombinant human monoclonal antibody with a binding specificity to epithelial cell adhesion molecule (Ep-CAM). Adecatumumab (MT201) is being evaluated in two European Phase 2 clinical trials, one in patients with prostate cancer, and one in patients with metastatic breast cancer.

Field of Use
The Field means the treatment of human diseases, disorders and conditions.

IPSCIO Record ID: 238982

License Grant
University hereby grants to Licensee an exclusive, worldwide right and license, with the right to grant Sublicenses and to permit Sub-sublicenses to practice under and use the Licensed Patents and the Licensed Technology to make, have made, use, market, sell, have sold, import, distribute, and offer for sale any Licensed Product, Licensed Process or Generic Product. University hereby agrees, subject to the terms and conditions herein contained, that the term 'exclusive' means that University shall not grant any other license to any third party or take any action inconsistent with the rights granted to Licensee under this Agreement relating to the Licensed Patents or Licensed Technology.
License Property
Licensed Patents shall mean the issued patents and the pending patent applications and made a part hereof, and any patents issuing therefrom, and any other patent applications not identified that have been filed or that may in the future be filed by Licensee on the Licensed Technology and any patents issuing therefrom, including any application(s) filed by Licensee, whether in the United States of America or any other country, including any and all substitutions for and divisions, continuations, continuation-in-part, provisionals, and non-provisionals, renewals, reissues, any foreign patent applications and divisionals or national phase applications which claim priority from any of the pending patent applications.

6,265,448 – Method for chemoprevention of prostate cancer
6,413,533 – Method for chemoprevention of prostate cancer
6,413,534 – Method for chemoprevention of prostate cancer
6,410,043 – Method for chemoprevention of prostate cancer
6,413,535 – Method for chemoprevention of prostate cancer

Licensed Product(s) shall mean any product that:
            (I)   is covered in whole or in part by a Valid Claim of the Licensed Patents; or
            (II)  is manufactured by using a process or is employed to practice a process which is covered in whole or in part by a Valid Claim of the Licensed Patents.

Licensed Technology shall mean any technology, trade secrets, methods, processes, know-how, show-how, data, information, or results relating to the patent applications, developed by the Contributors and owned by University, including the chemoprevention of prostate cancer and, more particularly, to a method of administering to a subject an effective dose of a chemopreventive agent or pharmaceutical preparation comprising an anti-estrogen or SERM, including, toremifene and analogs or metabolites thereof, to prevent recurrence of, suppress or inhibit prostate carcinogenesis.

Field of Use
This agreement pertains to the drug industry.

IPSCIO Record ID: 266840

License Grant
The University grants an exclusive, worldwide license under Licensor Know-How and Licensor Patent Rights to make, have made, use, and/or sell Licensed Products in the Field in the Territory.
License Property
Licensor has rights or has developed new anti-tumor bis-acridines, bis-ellipticines and bis-carbazoles known as Intercalating Agents.

Licensor Know-How shall mean the ideas, methods, characterization and techniques developed at the University before the Effective Date, which are necessary for practicing Licensor Patent Rights.

Field of Use
The Licensee plans to develop these innovative anti-cancer compounds as a new class of compounds for cancer treatment, unique among existing pharmacological treatments.

IPSCIO Record ID: 25786

License Grant
Licensee received an exclusive worldwide license from the University.  This includes the rights to sublicense and the intellectual property associated with SDX-101 and SDX-102, as well as issued patents and patent applications for several pre-clinical-stage projects, including the SDX-103 program.
License Property
SDX-101 is an oral compound which does not suppress the body’s immune system for the treatment of CLL. SDX-101 is an isomer, or component, of Lodine®, a marketed anti-inflammatory drug. The U.S. Food and Drug Administration, or FDA, has granted orphan drug status, a designation for drugs intended to treat a rare disease or condition affecting no more than 200,000 individuals in the U.S., for SDX-101 for the treatment of CLL.

SDX-102 is an intravenously administered small molecule which laboratory studies have shown kills tumors which cannot produce an important metabolic enzyme. Safety and tolerability data on SDX-102 were collected in clinical trials conducted at academic centers sponsored by the National Cancer Institute, or the NCI. These clinical trials tested the drug across a variety of cancers which are now known to produce this enzyme with a high frequency. The Licensee developed a proprietary, practical laboratory assay, or test, to identify patients whose cancers cannot produce this metabolic enzyme. In 2004, the Licensee was conducting Phase II trials of SDX-102 and are using their assay to select patients for these trials in difficult-to-treat cancers, including non-small cell lung cancer, or NSCLC, pancreatic and mesothelioma, none of which was previously studied by the NCI. The SDX-103 program involves analogs of the compound indanocine. Indanocine and indanocine analogs were synthesized and characterized at the University by the Licensee's founders. Indanocine displayed potent anti-proliferative activity when tested against a multitude of cancer cell lines at the NCI. These compounds differ from many clinically used drugs that block cell division in that they are active against multi-drug resistant cells and selectively kill non-dividing malignant cells. Anti-tumor activity of SDX-103 analogs has been observed in preliminary animal studies.

Field of Use
SDX-101 is covered by two use patents in the U.S. that prohibit third parties from using etodolac and etodolac analogs to treat CLL and NHL and R-etodolac and R-etodolac analogs to treat leukemias. These use patents expire in 2019. In the U.S. and selected foreign countries, the Licensee is pursuing additional use patents for etodolac, R-etodolac and etodolac analogs as well as composition of matter patents for etodolac analogs in the U.S. and in selected foreign countries.  SDX-102 and assay methods were covered by two use patents in the U.S. that prohibit third parties from using an assay to measure MTAP status in a patient and then treating with an adenyl succinate synthetase inhibitor such as alanosine. These patents expired in 2013. SDX-102 is also covered by a patent in the U.S. that prohibits third parties from treating multiple drug resistance in MTAP-deleted tumors using an adenine synthesis inhibitor, such as l-alanosine. A patent application covering an assay method and monoclonal antibody for determining the presence or absence of MTAP is currently pending. Similar applications are being pursued or have issued in selected foreign countries.

IPSCIO Record ID: 248277

License Grant
The Institute of Australia hereby grants to Licensee an exclusive license under the Licensed Patents and the Know-How in the Territory and within the Licensed Field to (a) make, have made, develop, use, practice, import, export, distribute, market, promote, offer for sale, and sell the Licensed Products, (b) use and practice any method, process, or procedure within the Licensed Patents, and (c) otherwise use and exploit the Licensed Patents.

The Institute hereby grants to Licensor an exclusive option to exclusively license any and all Improvement Inventions and Non-Improvement Inventions (the Option).

License Property
Licensed Patent shall mean any and all rights in and to: (i) the patent applications described below and all patents anywhere in the world issued thereon; and (ii) all continuations, continuations in part to the extent the claims are directed to subject matter specifically described in such corresponding parent application, divisionals, reexaminations, extensions, and reissue applications thereof, and all foreign applications and patents corresponding thereto, with respect to any of the foregoing applications.
U.S. Patent Application #61/392,296 – Small Molecules Inhibiting Oncoprotein MYC
U.S. Patent Application #61/423,832 – Small Molecules inhibiting Oncoprotein MYC

Licensed Product shall mean any and all products that employ or are in any way contains or is made or produced using, or by the practice of the Licensed Patents, licensed Improvement Inventions, the Technology, or the Know-How, including the drug candidates set forth.
· Drug summary: MYC inhibitor.
· Indications: Drugs for treatment of a broad range of solid tumors (breast, prostate, colon, non-small cell lung carcinoma, etc.) and hematological malignancies (various types of leukemia and lymphoma).
· Mechanism of action: CBLC-M compounds were generated to selectively target and inactivate oncoproteins of the Myc family, which are frequently upregulated in tumor cells. Although Myc has long been recognized as a highly attractive target for anti-cancer treatment, there are no experimental
or approved drugs targeting this transcription factor. CBLC-M compounds target Myc family proteins with a high degree of specificity and cause their selective degradation. This mechanism of action is translated into both a direct tumor-suppressive effect and increased susceptibility of tumor cells to conventional chemotherapeutic drugs. Combining CBLC-M with such drugs as doxorubicin, 5FU, irinotecan and others within composite nanoparticles will result in improved anti-tumor effects due to precise targeted drug delivery that will concentrate the synergistic effects of the combined compounds on the tumor cells while reducing toxicity to normal cells.

Option Products shall mean Licensed Products and any and all products that employ or are in any way contained or made or produced using, or by the practice of the Projects set forth.

Improvement Invention shall mean any Institute Invention and Institute’s rights as a joint owner in a Joint Invention that is sufficiently different from the scope of a Licensed Patent to be separately patentable, and covered by the claims of Licensed Patents.
Non-Improvement Invention shall mean any Institute Invention and Institute’s rights as a joint owner in a Joint Invention that is not an Improvement Invention.

Field of Use
The rights granted apply to the healthcare industry.  Licensed Field shall mean all fields of use.

IPSCIO Record ID: 293074

License Grant
Licensor grants a license to make, use, sell, offer for sale, and import Licensed Products in the Field of Use in the Territory under its Licensed Rights, together with the right to sublicense.   Such license shall be exclusive as to the Patent Rights, and nonexclusive as to the Licensed Know-How.
License Property
The patents and know-how include and relate to A Small-Molecule Pan-Id Antagonist Inhibits Pathologic Ocular Neovascularization.

Licensed Product shall mean AGX-A or its analogs as described in the Patent Rights, related products and processes.

AGX-A shall mean the compound N-benzyl-3-(4-isopropoxyphenyl)-3-(2-methoxyphenyl)propan-1-amine and includes pharmaceutically acceptable salts of N-benzyl-3-(4-isopropoxyphenyl)-3-(2-methoxyphenyl)propan-1-amine as described in U.S. Provisional Application No. 62/909,036 filed October 1, 2019. )

Field of Use
This license for Novel Compounds for Inhibition of Id is for all fields of use.   Licensee intends to advance a series of anti-ID compounds through the regulatory process and into human clinical trials.  Recent in vitro and in vivo work identified a biological mechanism that allows certain fatal cancers of the liver, brain and breast to regenerate despite their apparent elimination by surgery, chemotherapy or radiation.  Recent results indicate a fundamental mechanism, common to a significant group of cancers that allows these diseases to marshal a set of ID proteins which enable their persistent recurrence and lethality.

The scientific team has in its recent in vitro and in vivo work identified a biological mechanism that allows certain fatal cancers of the liver, brain and breast to regenerate despite their apparent elimination by surgery, chemotherapy or radiation.

IPSCIO Record ID: 4661

License Grant
The parties entered into an exclusive license agreement to develop and commercialize lucitanib on a global basis, excluding China.
License Property
Lucitanib is an oral, potent inhibitor of the tyrosine kinase activity of fibroblast growth factor receptors 1 through 3 (FGFR1-3), vascular endothelial growth factor receptors 1 through 3 (VEGFR1-3) and platelet-derived growth factor receptors alpha and beta (PDGFR α-ß).
Field of Use
A Phase I/IIa clinical trial of lucitanib was initiated in 2010 and has demonstrated multiple objective responses in FGFR1 gene-amplified breast cancer patients, and objective responses were also observed in patients with tumors often sensitive to VEGFR inhibitors, such as renal cell and thyroid cancer. FGFR amplification is common in a number of tumor types, including breast cancer and squamous non-small cell lung cancer, and we intend to study lucitanib in these cancers as well as other solid tumors exhibiting FGFR pathway activation.
Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.